Free Webcast On How To Use Materials Science Principles To Reduce Pharmaceutical Formulation Risks
NEW YORK, April 3, 2013 /PRNewswire/ -- Pharmaceutical excipients were once called "inert" ingredients. That was before scientists understood how they can react with active pharmaceutical ingredients (APIs) and other ingredients of drug tablets and capsules. A failure to understand potential reactions can result in variable product quality and even adverse reactions in patients who must take these medications.
Protecting patients and reducing the risk of pharmaceutical formulation requires a clear understanding of ingredient interactions, at the molecular level. The materials science principles behind each constituent ingredient and its potential interactions with others must be controlled.
On Thursday, April 11, 2013, at 9:00 a.m. ET, Paul Trusty, a materials science PhD and technical director of solid dosage forms at GSK, will discuss these issues and offer best-practices for reducing the risk of pharmaceutical formulations, in a free webcast sponsored by PharmaEvolution.com.
The one-hour program will focus on developing a "microstructure property approach," to review key risks and how they can be controlled at the particulate level. It will also examine excipient functionality and discuss modern visualization and analytical techniques that can be used to better understand material structure at a microscopic level.Mr. Trusty will also discuss how to optimize release rate and uptake by understanding how each constituent ingredient contributes to tablet breakup. In addition, he will show how to apply pharmaceutical quality by design (QbD) approaches to formulation, and better understand the relationships among structure, property and performance. Mr. Trusty is responsible for global tech support at GSK, from new product development to scaleup, tech transfer, CMC registration, and product launch. The webcast is sponsored by PharmaEvolution.com ( www.pharmaevolution.com), a new online community for professionals who work in pharmaceutical research and development, manufacturing, supply chain management, and quality. The site is published by UBM DeusM and CPhI worldwide. For more information and to register for the webcast, click here. http://www.pharmaevolution.com/webinar.asp?webinar_id=9 Contact Amy AverbookSr. Marketing DirectorUBM DeusM email@example.com About CPhI Worldwide CPhI Worldwide was first held in 1990 and 2012 marks the 23rd edition of this prestigious and industry leading event. From just 250 delegates at the inaugural convention, visitors' number has subsequently grown more than one hundred fold to more than 30,000 attendees from over 133 countries. The event now hosts 2,200 exhibitors and is the market leader for the global pharmaceutical industry. CPhI Worldwide has three co-located events: ICSE, P-MEC Europe and InnoPack. These events focus on specific sub-sectors of the pharma ingredients industry and provide visitors and exhibitors with additional capability to network and do business in dedicated areas. About UBM DeusMUBM DeusM ( www.deusm.com) is an integrated marketing services company owned by UBM plc, targeting the fastest growing segment of the online publishing industry: business social media. The company is led by Managing Director Stephen Saunders, Min's Marketer of the Year 2010. He and the other UBM DeusM principals have built and delivered more than forty-five successful sites and online communities over the last 2 years. UBM DeusM's service is based on a unique platform, called Community in a Box (CiaB), which employs a structured system of proven B2B Web publishing best-practices, combined with a breakthrough integrated multimedia publishing platform ("n-Server") to enable marketers to quickly and profitably set up specialized communities for their target customers. SOURCE CPhI Worldwide
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts